Home > Search Results
  • Showing results for ecog. Your search for CECXG retrieved no results.

Results: 1 to 20 of 82

Utility of electrocorticography in the surgical treatment of cavernomas presenting with pharmacoresistant epilepsy

AIM: To describe the general aspects of cavernomas and epilepsy and review the available literature on the utility of electrocorticography (ECoG) in cerebral cavernoma surgery.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

This review found that the research conducted in the area of chemoradiation for adult patients with locally advanced non-small cell lung cancer was generally of poor quality and suffered from a lack of reporting of all important clinical findings. The trials included in the systematic review were too disparate to form any firm conclusions as to the effectiveness of individual chemotherapy agents or types of radiotherapy.

Health Technology Assessment - NIHR Journals Library.

Version: February 2013
Show search results within this document

Denosumab (Xgeva) [Internet]

Bone is a common site of metastasis for many cancers including breast, prostate, thyroid, lung, renal, and melanoma. Skeletal metastatic disease is the cause of considerable morbidity in patients with advanced cancer and has been associated with an increase in cancer-related pain, hypercalcemia, fractures, spinal instability, and compression of the spinal cord.

Common Drug Review - Canadian Agency for Drugs and Technologies in Health.

Version: November 2016
Show search results within this document

DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment [Internet]

Testing tumours for deficient DNA mismatch repair (dMMR) has been identified as a practice that is potentially over-utilized. According to clinical experts, dMMR tumour testing appears to be transitioning from an approach aimed at identifying patients and families with Lynch syndrome (LS) into a tumour phenotyping procedure that can be used to predict the prognosis of colorectal cancer (CRC) and to guide for adjuvant chemotherapy decisions. The use of a test with a prognostic and predictive value falls under the realm of “personalized medicine.” According to oncology and pathology experts, this recent application of dMMR tumour testing is the major driver of new test requisitions. This transition has led to an increased demand for the test, with unclear benefits for the patient or family members. In general, there is a lack of clarity regarding when the tests should be ordered and the impact of tumour dMMR status on CRC outcomes in the current era of oxaliplatin- and irinotecan-based chemotherapy. The central question, however, is whether universal dMMR tumour testing of CRC tumours is a viable and desirable option, given the known limitations of LS pre-selection criteria based on age, history, and pathology, and recognizing the potential utility of tumour dMMR status for personalizing cancer therapy. Missed cases of LS resulting from a targeted tumour dMMR testing strategy that is restricted to pre-selected high-risk individuals (e.g., selected based on the rBG) can be problematic and costly for the system, which would potentially support broader (universal) dMMR tumour testing of all CRC tumours. Alternatively, universal tumour testing carries with it additional costs associated with testing all CRC patients, most of whom will not have LS.

CADTH Optimal Use Report - Canadian Agency for Drugs and Technologies in Health.

Version: August 2016
Show search results within this document

Emerging Approaches to Diagnosis and Treatment of Non–Muscle-Invasive Bladder Cancer [Internet]

Non–muscle-invasive bladder cancer (NMIBC) frequently recurs and can progress to muscle-invasive disease. This report reviews the current evidence on emerging approaches to diagnosing and treating bladder cancer.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: October 2015
Show search results within this document

The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation

Study found that there is limited evidence on the clinical effectiveness and cost-effectiveness of ablative and other minimally invasive therapies for treating people with liver metastases. Results are presented for a number of ablative and minimally invasive therapies, but all studies had methodological shortcomings, few had a comparator group and there were with limited analyses and many uncertainties. There is scope for further research.

Health Technology Assessment - NIHR Journals Library.

Version: January 2014
Show search results within this document

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

The study found that denosumab is effective in delaying skeletal related events in patients with bone metastases from solid tumours but is only cost-effective relative to zoledronic acid with a patient access scheme, without such a scheme it is not cost-effective relative to zoledronic acid or best supportive care.

Health Technology Assessment - NIHR Journals Library.

Version: July 2013
Show search results within this document

Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis

Breast cancer is the uncontrolled, abnormal growth of malignant breast tissue affecting predominantly women. Metastatic breast cancer (mBC) is an advanced stage of the disease when the disease has spread beyond the original organ. Hormone receptor status and human epidermal growth factor 2 (HER2) status are two predictive factors that are taken into consideration when estimating the prognosis of patients with breast cancer.

Health Technology Assessment - NIHR Journals Library.

Version: December 2011
Show search results within this document

Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling

Study found that the addition of PET-CT to standard practice is not cost-effective in the diagnosis of recurrent or persistent cervical cancer but that should more reliable information become available on accuracy, therapeutic impact and effectiveness, and the cost of PET-CT decrease, this conclusion may need revision

Health Technology Assessment - NIHR Journals Library.

Version: March 2013
Show search results within this document

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation

Study provides a comprehensive framework of information for three subpopulations of patients with non-small cell lung cancer that clinicians can refer to as they attempt to balance patient factors, available treatments, treatment costs and adverse events in their daily decision-making.

Health Technology Assessment - NIHR Journals Library.

Version: July 2013
Show search results within this document

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation

The study was unable to compare the clinical and cost-effectiveness of platinum-based therapies with non-platinum-based therapies for platinum sensitive ovarian cancer. In people with platinum-sensitive disease, paclitaxel plus platinum could be considered cost-effective compared with platinum therapies alone at a threshold of £30,000 per additional quality-adjusted life-year. In people with disease which is resistant or refractory to platinum it is unlikely that topotecan would be considered cost-effective compared with pegylated liposomal doxorubicin hydrochloride.

Health Technology Assessment - NIHR Journals Library.

Version: January 2015
Show search results within this document

A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression

Study reports that clinical consensus favours magnetic resonance imaging and computerised tomography for identifying patients with malignant spinal metastases who are at high risk of vertebral fracture and spinal cord compression.

Health Technology Assessment - NIHR Journals Library.

Version: September 2013
Show search results within this document

Care of Dying Adults in the Last Days of Life

This guideline applies to dying people aged 18 or older. It is acknowledged that a parallel guideline is being developed by NICE to cover the end of life care for infants, children and young people.

NICE Guideline - National Clinical Guideline Centre.

Version: December 16, 2015
Show search results within this document

The delivery of chemotherapy at home: an evidence synthesis

The study found that trials comparing different settings for delivering intravenous chemotherapy appear difficult to conduct. Consequently, few conclusions can be reached regarding the clinical effectiveness and cost-effectiveness of the home, community and outpatient settings. Future studies could produce more informative data if careful consideration is given to study design.

Health Services and Delivery Research - NIHR Journals Library.

Version: April 2015
Show search results within this document

Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation

Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.

Health Technology Assessment - NIHR Journals Library.

Version: June 2011
Show search results within this document

Depression in Adults with a Chronic Physical Health Problem: Treatment and Management

This clinical guideline was commissioned by NICE and developed by the National Collaborating Centre for Mental Health. It sets out clear, evidenceand consensus-based recommendations for healthcare staff on how to treat and manage depression in adults with a chronic physical health problem.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2010
Show search results within this document

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model

Study found that, although cetuximab and panitumumab appear to be clinically beneficial for the treatment of metastatic colorectal cancer in Kirsten rat sarcoma (KRAS) wild-type patients compared with best supportive care, they are likely to represent poor value for money when judged by cost-effectiveness criteria currently used in the UK.

Health Technology Assessment - NIHR Journals Library.

Version: April 2013
Show search results within this document

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis

Study found that there was no strong evidence that any one KRAS mutation test was more effective or cost-effective than any other test for differentiating adults with metastatic colorectal cancer whose metastases are confined to the liver and are unresectable and who may benefit from first-line treatment with cetuximab in combination with standard chemotherapy from those who should receive standard chemotherapy alone.

Health Technology Assessment - NIHR Journals Library.

Version: October 2014
Show search results within this document

Stereotactic Body Radiation Therapy [Internet]

Conduct a systematic literature scan for published data for the treatment of stereotactic body radiation therapy (SBRT) and provide a broad overview of the current state of SBRT for solid malignant tumors.

Comparative Effectiveness Technical Briefs - Agency for Healthcare Research and Quality (US).

Version: May 2011
Show search results within this document

Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines [Internet]

The aim of this report is to review the clinical effectiveness, cost-effectiveness, and evidence-based guidelines of radium-223 (Ra-223) in patients with bone metastatic castration-resistant prostate cancer (mCRPC).

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: October 31, 2016
Show search results within this document

Systematic Reviews in PubMed

See all (89)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...